Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 32Cyclophosphamide 16Busulfan 16fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 13Filgrastim 13Idarubicin 11Etoposide 11Antilymphocyte Serum 10Cyclosporine 9Mitoxantrone 8Radiotherapy 7Methotrexate 7Daunorubicin 7Whole-Body Irradiation 5Tacrolimus 5Cord Blood Stem Cell Transplantation 5Clofarabine 5Mycophenolic Acid 4Methylprednisolone 4Flow Cytometry 4Arsenic Trioxide 4aldesleukin 3Topotecan 3Thiotepa 3Melphalan 3Imatinib Mesylate 3Gemtuzumab 3Cytogenetic Analysis 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Megakaryoblastic, Acute × Drug Screening Assays, Antitumor × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡